New Multiple Sclerosis Treatment Options

Since many people don't know about autoimmune diseases, in this article we will analyze the new multiple sclerosis treatment options.
New Multiple Sclerosis Treatment Options

Last update: 21 June, 2021

Multiple sclerosis is a serious, chronic, unpredictable, and physically disabling condition. It can range from relatively mild to severe. That’s why it’s so important to study the new multiple sclerosis treatment options currently available.

In this condition, there’s a change or lack of regulation of the immune system, and it affects the central nervous system (CNS). In other words, it makes the body destroy its own cells. Also, it affects the connections of the brain with the rest of the body.

What is multiple sclerosis?

Multiple sclerosis means “multiple hardening or scarring.” This means that there’s a hardening, inflammation, and destruction of important parts of our cells. In addition, it mostly affects different parts of the brain.

In the brain, there’s an area called white matter. This is made up of neuron fibers wrapped in myelin. Neurons are brain cells, and myelin transmits messages from the brain. 

As a result, the white matter becomes inflamed, and, as a result, the myelin gets damaged. Consequently, it slows or stops sending messages between the brain, spinal cord and the rest of the body.

Mainly, multiple sclerosis symptoms appear between the ages of 20 and 40. However, the diagnosis is often late because there isn’t a specific test for it.

There are risk factors for the development of the disease, such as:

  • Being caucasian
  • Being a women
  • Living in temperate climates
A woman feeling fatigued.

New multiple sclerosis treatment options

Mainly, the goals of treating multiple sclerosis are to slow its progress and manage its symptoms. Therefore, the main purposes of treatment are:

  • Slowing down brain involvement
  • Slowing down the disability it causes
  • Reducing the number of flare-ups
  • Improving brain-body connections
  • Decreasing pain
  • Giving support and psychological help
  • Improving the quality of life

Before looking at new treatments, we need to know what basic options improve this disabling disease that affects so many people around the world.

Fortunately, although sometimes it doesn’t help to make the disease go away, there are different forms of multiple sclerosis treatment, such as:

Symptomatic treatment

This aims to improve the quality of life, as well as reduce the symptoms of illness and disability. There are different symptomatic ways to treat multiple sclerosis. For example:

  • Passive rehabilitation: This is performed by professional physical therapists.
  • Active rehabilitation: This is carried out by the patients themselves.
  • Injection therapies: These improve specific muscles.
  • Pharmacological treatment: For example, you could use corticosteroids that reduce inflammation.
  • Orthopedic surgery: This improves the alignment of tendons, bones, and muscles that have lost mobility.
  • Brain surgery: These can help treat inflamed or hardened nerve fibers.
A woman doing physical therapy.

You might be interested in: Multiple Sclerosis: A Multi-Faceted Disease

Acute treatment

When there’s an outbreak and the person is suffering, a more comprehensive and intense symptomatic treatment is used. Generally, it happens in a relatively short amount of time.

New treatment options

Specialists could use disease-modulating therapy to prevent further injury or disease progression.

This therapy is based on immunosuppression or immunomodulatory drugs. These control the immune response to prevent cells from becoming inflamed and/or destroying themselves. In other words, it stops the body from thinking its own cells are invasive.

The goal of these therapies is mainly to control inflammation. It also helps to reduce the appearance of flare-ups in the short term. It all boils down to slowing down the disease so it doesn’t get worse.

Examples of these medications are:

  • First options: Interferon-beta and Copaxone.
  • The second line of treatment: Natalizumab and fingolimod.

New multiple sclerosis treatment options

However, sometimes multiple sclerosis treatment isn’t very effective, and this is mainly due to the late diagnosis of this disease.

Therefore, it’s important that, before seeing any signs of disability, you talk to your doctor to rule out this pathology as soon as possible. If it’s not ruled out, you can prevent it from getting worse by using these new forms of treatment.

It might interest you...
5 Things You Should Know About Autoimmune Diseases
Step To Health
Read it in Step To Health
5 Things You Should Know About Autoimmune Diseases

The majority of these conditions tend to be a mystery for science. Learn more about autoimmune diseases from this article.

  • GAEM F. TRATAMIENTOS DE LA ESCLEROSIS MÚLTIPLE [Internet]. [cited 2020 May 10]. Available from:
  • Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, et al. Switching from natalizumab to fingolimod in multiple sclerosis: A French prospective study. JAMA Neurol. 2014;71(4):436–41.
  • Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, et al. Switching from natalizumab to fingolimod : A randomized, placebo-controlled study in RRMS. Neurology. 2015 Jul 7;85(1):29–39.
  • Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000 Sep 28;343(13):898–904.
  • McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, et al. Stratification and monitoring of natalizumabassociated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016 Feb 1;87(2):117–25.
  • Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Vol. 4, Multiple Sclerosis and Related Disorders. Elsevier B.V.; 2015. p. 329–33.
  • García Merino A, Ramón Ara Callizo J, Fernández Fernández O, Landete Pascual L, Moral Torres E, Rodríguez-Antigüedad Zarrantz A. Consenso para el tratamiento de la esclerosis múltiple 2016. Sociedad Española de Neurología. Vol. 32, Neurologia. Spanish Society of Neurology; 2017. p. 113–9.